EUCTR2009-016068-35-BE进行中（未招募）不适用
A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - ALIG
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •I 01. Patients with active AS based on the Modified New York criteria for ankylosing
- •spondylitis.
- •I 02. Patients must had an adequate trial of at least 2 different NSAIDs taking for at least 2 weeks in each case and on a stable dose for =2 weeks or be intolerant to NSAIDs.
- •I 03. Active disease must be present for =3 months and be present at screening and at baseline as defined:
- •- Bath AS Disease Activity Index (BASDAI) score of =4 (NRS 0-10);
- •- Total back pain score =4 (NRS 0-10).
- •I 04. Patients treated with corticosteroid must be on a stable dose for >2 weeks prior to baseline.
- •I 05. Patients treated with DMARDs: hydroxychloroquine, sulfasalazine and MTX must be on a stable dose =12 weeks.
- •I 06. Patients must give informed consent prior to any procedure related to the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •E 01. Male and female patients age <18 of age or =75 years.
- •E 02. Weight <50 kg for man or <45 Kg for women or >110 kg for both man or women.
- •E 03. BASDAI score <4 (NRS 0-10) at screening and baseline.
- •E 04. Total Back Pain score <4 (NRS 0-10) at screening and baseline.
- •E 05. Patients with complete fusion of the spine.
- •E 06. Patient who has previously participated in any clinical trial of SAR153191.
- •E 07. Participation in any clinical research study evaluating another investigational drug or therapy within 60 days or at least 5 half-lives, whichever is longer, of
- •investigational drug, prior to Screening Visit.
- •E 08. Have a history or presence of significant other concomitant illness according to the investigator’s judgment.
- •E 09. Conditions/situations such as:
- •- Patients with short life expectancy;
- •- Patients with conditions/concomitant diseases making them non-evaluable for
- •primary efficacy endpoint;
- •- Requirement for concomitant treatment that could bias primary evaluation;
- •- Impossibility to meet specific protocol requirements;
- •- Patient is the Investigator or any sub-Investigator, research assistant, pharmacist,
- •study coordinator, other staff or relative thereof directly involved in the conduct of
- •- Uncooperative or any condition that could make patient potentially
- •non-compliant with study procedures.
- •E 10. Starting treatment with NSAIDs <4 weeks prior to screening or change current
- •treatment or dose for =2 weeks prior to baseline.
- •E 11. Treatment with oral prednisone or equivalent corticosteroids >10 mg/day within
- •6 weeks prior to screening.
- •E 12. Use of intramuscular or intra-articular corticosteroids within last 4 weeks before screening.
- •E 13. Patients who had previously been treated or are currently treated with Disease
- •Modifying Anti-Rheumatic Drugs or with cyclosporine, azathioprine, or DMARDs
- •other than methotrexate, sulfasalazine and hydroxychloroquine; and must be on stable dose for =12 weeks; and not to exceed following dose:
- •- Methotrexate >25 mg/week;
- •- Hydroxychloroquine >400 mg/day;
- •- Sulfasalazine >3 gr/day.
- •E 14. Past history of non response to any anti-TNFs treatment or non response to any other biological treatment for AS.
- •E 15. Any past or current treatment with anti-TNFs agents or any biological agent within 3 months from screening.
- •E 16. Pregnant or breast-feeding women.
- •E 17. For women of childbearing potential, unwillingness to utilize adequate contraception or not become pregnant during full course of study.
- •E 18. History of alcohol or drug abuse within the 5 years prior to Screening Visit.
- •E 19. Any subject who has had surgery within 4 weeks prior to Screening Visit or with planned elective surgery.
- •E 20. History of malignancy other than effectively treated carcinoma in-situ of cervix, or adequately treated, non-metastatic squamous or basal cell carcinoma of skin within five years prior to Screening Visit. History of lymphoproliferative disease or possible current lymphoproliferative disease.
- •E 21. Patients with latent or active tuberculosis.
- •E 22. Patients with history of Listeriosis or tuberculosis (unless documented that it was adequately treated) (see Section 10.2).
- •E 23. Fever (=38°C) or persistent chronic or active recurring infection requiring treatment with antibiotics, antivirals, or antifungals within 4 weeks prior to the Screening Visit, or history of frequent recurrent infections unacceptable per investigator judgment.
- •E 24. Unhealed infected skin ulcers.
- •E 25. Received administration
研究者
相似试验
尚未招募
2 期
A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS)Bechterew's diseaseMarie Strümpell disease10007951NL-OMON34801Sanofi-aventis8
进行中（未招募）
不适用
A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - ALIGAnkylosing SpondylitisEUCTR2009-016068-35-DESanofi-aventis Recherche & Développement300
进行中（未招募）
不适用
A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - ALIGMedDRA version: 12.0Level: LLTClassification code 10002556Term: Ankylosing spondylitisAnkylosing SpondylitisEUCTR2009-016068-35-ATSanofi-aventis Recherche & Développement300
进行中（未招募）
不适用
A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - ALIGMedDRA version: 12.0Level: LLTClassification code 10002556Term: Ankylosing spondylitisAnkylosing SpondylitisEUCTR2009-016068-35-CZSanofi-aventis Recherche & Développement300
进行中（未招募）
不适用
A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - ALIGMedDRA version: 12.0Level: LLTClassification code 10002556Term: Ankylosing spondylitisAnkylosing SpondylitisEUCTR2009-016068-35-NLSanofi-aventis Recherche & Développement300